Eli Lilly and Company, Merck & Co., Inc., Gilead Sciences, AbbVie, Bristol Myers Squibb, Amgen, and Abbott Laboratories are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and market prescription drugs, vaccines, and related medical products. Because their value often hinges on factors like patent lifecycles, clinical-trial outcomes, regulatory approvals, and competitive pipelines, they can exhibit higher volatility compared to many other sectors. Investors in pharmaceutical stocks typically weigh scientific breakthroughs and approval timelines alongside broader market and healthcare-policy trends. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of Eli Lilly and Company stock traded down $21.61 during trading on Friday, hitting $763.43. 6,197,089 shares of the company's stock traded hands, compared to its average volume of 3,667,759. The company has a market cap of $723.53 billion, a PE ratio of 62.12, a PEG ratio of 1.15 and a beta of 0.40. The firm's fifty day moving average price is $780.48 and its 200 day moving average price is $801.13. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06.
Read Our Latest Research Report on LLY
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
MRK traded down $0.05 during midday trading on Friday, reaching $79.24. 33,825,641 shares of the company's stock were exchanged, compared to its average volume of 13,058,098. The company has a quick ratio of 1.16, a current ratio of 1.41 and a debt-to-equity ratio of 0.69. The business has a 50-day simple moving average of $78.89 and a two-hundred day simple moving average of $88.52. The firm has a market capitalization of $198.98 billion, a price-to-earnings ratio of 11.53, a price-to-earnings-growth ratio of 0.82 and a beta of 0.38. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $134.63.
Read Our Latest Research Report on MRK
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Shares of GILD traded up $0.50 during mid-day trading on Friday, reaching $108.50. The company had a trading volume of 23,266,621 shares, compared to its average volume of 7,756,139. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The company has a market capitalization of $134.97 billion, a P/E ratio of 22.84, a P/E/G ratio of 0.70 and a beta of 0.29. Gilead Sciences has a twelve month low of $66.01 and a twelve month high of $119.96. The company's 50-day moving average is $106.16 and its 200-day moving average is $102.74.
Read Our Latest Research Report on GILD
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
NYSE:ABBV traded down $0.33 during trading hours on Friday, reaching $185.16. The company had a trading volume of 12,149,354 shares, compared to its average volume of 6,268,431. The company has a quick ratio of 0.64, a current ratio of 0.76 and a debt-to-equity ratio of 44.14. The stock has a 50-day moving average of $185.19 and a two-hundred day moving average of $187.63. AbbVie has a one year low of $163.52 and a one year high of $218.66. The firm has a market capitalization of $327.06 billion, a PE ratio of 78.79, a PEG ratio of 1.23 and a beta of 0.50.
Read Our Latest Research Report on ABBV
Bristol Myers Squibb (BMY)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Shares of NYSE:BMY traded up $0.03 on Friday, hitting $46.87. The stock had a trading volume of 47,283,703 shares, compared to its average volume of 13,081,197. The firm's 50 day moving average price is $48.20 and its 200-day moving average price is $54.35. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. Bristol Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The company has a market capitalization of $95.38 billion, a price-to-earnings ratio of 17.55, a price-to-earnings-growth ratio of 1.39 and a beta of 0.38.
Read Our Latest Research Report on BMY
Amgen (AMGN)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
AMGN stock traded down $0.30 during trading on Friday, hitting $289.33. 6,801,322 shares of the stock traded hands, compared to its average volume of 2,835,249. The stock has a market cap of $155.58 billion, a price-to-earnings ratio of 26.40, a P/E/G ratio of 2.62 and a beta of 0.51. Amgen has a one year low of $253.30 and a one year high of $346.85. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70. The company has a 50 day simple moving average of $281.82 and a 200 day simple moving average of $285.96.
Read Our Latest Research Report on AMGN
Abbott Laboratories (ABT)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Shares of ABT traded up $0.47 on Friday, hitting $132.88. The company's stock had a trading volume of 11,316,722 shares, compared to its average volume of 6,120,549. The company has a 50 day moving average price of $132.19 and a 200 day moving average price of $126.88. Abbott Laboratories has a fifty-two week low of $99.71 and a fifty-two week high of $141.23. The company has a market capitalization of $231.20 billion, a PE ratio of 17.24, a PEG ratio of 2.51 and a beta of 0.73. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.78 and a quick ratio of 1.27.
Read Our Latest Research Report on ABT
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
